U.S. patent application number 10/514740 was filed with the patent office on 2005-10-06 for fusion protein of hiv regulatory/accessory proteins.
Invention is credited to Felder, Eva, Howley, Paul, Leyrer, Sonja.
Application Number | 20050222388 10/514740 |
Document ID | / |
Family ID | 29433046 |
Filed Date | 2005-10-06 |
United States Patent
Application |
20050222388 |
Kind Code |
A1 |
Howley, Paul ; et
al. |
October 6, 2005 |
Fusion protein of hiv regulatory/accessory proteins
Abstract
The invention relates to fusion proteins comprising the amino
acid sequence of at least four HIV proteins selected from Vif, Vpr,
Vpu, Rev, Tat and Nef or derivatives of the amino acid sequence of
one or more of said proteins, wherein the fusion protein is not
processed to individual HIV proteins having the natural N and C
termini. The invention further concerns nucleic acids encoding said
proteins, vectors comprising said nucleic acids, and methods for
producing said proteins. The fusion protein, nucleic acids and
vectors are usable as vaccines for the at least partial prophylaxis
against HIV infections.
Inventors: |
Howley, Paul; (Glen Waverly,
AU) ; Leyrer, Sonja; (Munich, DE) ; Felder,
Eva; (Munich, DE) |
Correspondence
Address: |
THE FIRM OF KARL F ROSS
5676 RIVERDALE AVENUE
PO BOX 900
RIVERDALE (BRONX)
NY
10471-0900
US
|
Family ID: |
29433046 |
Appl. No.: |
10/514740 |
Filed: |
November 15, 2004 |
PCT Filed: |
May 14, 2003 |
PCT NO: |
PCT/EP03/05039 |
Current U.S.
Class: |
530/350 |
Current CPC
Class: |
A61K 39/12 20130101;
A61K 2039/5256 20130101; A61K 39/21 20130101; A61K 2039/53
20130101; C07K 2319/40 20130101; C07K 2319/00 20130101; C12N
2710/24143 20130101; A61P 37/04 20180101; C12N 2740/16334 20130101;
C07K 14/005 20130101; A61P 31/18 20180101; C12N 2740/16322
20130101; C12N 15/86 20130101 |
Class at
Publication: |
530/350 |
International
Class: |
C07K 014/16 |
Foreign Application Data
Date |
Code |
Application Number |
May 16, 2002 |
DK |
PA 200200754 |
Claims
1. A fusion protein comprising the amino acid sequence of at least
four HIV proteins selected from Vif, Vpr, Vpu, Vpx, Rev, Tat and
Nef or derivatives of the amino acid sequence of one or more of
said proteins, wherein the fusion protein is not processed to
individual HIV proteins having the natural N and C termini and
wherein a derivative of the amino acid sequence of an HIV protein
is an amino acid sequence showing a homology of at least 50%, when
the corresponding part of the amino acid sequence in the fusion
protein is compared to the amino acid sequence of the respective
HIV protein of known HIV isolates.
2. Fusion protein according to claim 1, wherein the homology is at
least 80%.
3. Fusion protein according to claim 1, wherein not more than 10
amino acids are deleted, inserted or substituted in the derivative
of the amino acid sequence when compared to the amino acid sequence
of the respective HIV protein of known HIV isolates to obtain an
HIV protein with reduced activity or no activity at all.
4. Fusion protein according to anyone of claims 1 to 3, wherein the
HIV proteins are selected from Vif, Vpr, Vpx, Vpu, Rev and Tat
5. Fusion protein according to anyone of claims 1 to 4, comprising
the amino acid sequence of the HIV proteins Vif, Vpr, Vpu, Rev and
Tat or derivatives of the amino acid sequence of one or more of
said proteins.
6. Fusion protein according to anyone of claims 1 to 5, wherein the
amino acid sequences of at least two of the HIV proteins are fused
to each other without additional amino acids.
7. Fusion protein according to anyone of claims 1 to 6, wherein the
amino acid sequences of at least two of the HIV proteins are
separated by at least one additional amino acid.
8. Fusion protein according to anyone of claims 1 to 7, wherein the
amino acid sequence of at least one of the HIV proteins is fused to
a fusion partner which is not a HIV protein selected from Vif, Vpr,
Vpx, Vpu, Rev, Tat and Nef.
9. Nucleic acid encoding a fusion protein according to anyone of
claims 1 to 8.
10. Nucleic acid according to claim 9, wherein the nucleic acid is
DNA.
11. Nucleic acid according to claim 10, wherein the expression of
the fusion protein from the DNA is controlled by regulatory
elements selected from eukaryotic, procaryotic and viral
promoters.
12. Nucleic acid according to claim 11, wherein the viral promoter
is a poxyiral promoter.
13. Nucleic acid according to anyone of claims 9 to 12, wherein the
nucleic acid further comprises the coding sequence for at least one
additional HIV protein selected from Gag, Pol and Env.
14. Nucleic acid according to claim 13, wherein the nucleic acid
comprises the coding sequence for the HIV Gag, Pol and Env
proteins.
15. Vector comprising a nucleic acid according to anyone of claims
9 to 14.
16. Vector according to claim anyone of claims 15, wherein the
vector is a viral vector.
17. Vector according to claim 16, wherein the viral vector is a
poxvirus vector, in particular a Vaccinia Virus vector.
18. Vector according to claim 17, wherein the Vaccinia virus vector
is Modified Vaccinia Virus Ankara (MVA).
19. Vector according to claim 18, wherein MVA is selected from
MVA-575 deposited at the European Collection of Animal Cell
Cultures (ECACC) under the deposition number V00120707 and MVA-BN
deposited at the ECACC under the deposition number V00083008.
20. Method of producing a protein according to anyone of claims 1
to 8, comprising the steps of transfecting a host cell with a
nucleic acid according to anyone of claims 9 to 14 or a with a
vector according claim 15 or infecting a host cell with a viral
vector according to anyone of claims 16 to 19, expressing the
fusion protein in the transfected host cell or the infected host
cell, and recovering the fusion protein.
21. Host cell transfected with a nucleic acid according to anyone
of claims 9 to 14 or a vector according to claim 15 or infected
with a viral vector according to anyone of claims 16 to 19.
22. Fusion protein according to anyone of claims 1 to 8, nucleic
acid according to anyone of claims 9 to 14 or vector according to
anyone of claims 15 to 19 as a medicament.
23. Fusion protein according to anyone of claims 1 to 8, nucleic
acid according to anyone of claims 9 to 14 or vector according to
anyone of claims 15 to 19 as a vaccine.
24. Vaccine comprising a fusion protein according to anyone of
claims 1 to 8, a nucleic acid according to anyone of claims 9 to 14
or a vector according to anyone of claims 15 to 19.
25. Use of a fusion protein according to anyone of claims 1 to 8,
of a nucleic acid according to anyone of claims 9 to 14 or of a
vector according to anyone of claims 15 to 19 for the preparation
of a vaccine.
26. Method for protecting an animal, including a human, against an
HIV infection by administering to an animal, including a human, in
need thereof a fusion protein according to anyone of claims 1 to 8,
a nucleic acid according to anyone of claims 9 to 14 or a vector
according to anyone of claims 15 to 19.
Description
[0001] The invention relates to fusion proteins comprising the
amino acid sequence of at least four HIV proteins selected from
Vif, Vpr, Vpu, Vpx, Rev, Tat and Nef or derivatives of the amino
acid sequence of one or more of said proteins, wherein the fusion
protein is not processed to individual HIV proteins having the
natural N and C termini. The invention further concerns nucleic
acids encoding said proteins, vectors comprising said nucleic
acids, and methods for producing said proteins. The fusion protein,
nucleic acids and vectors are usable as vaccines for the at least
partial prophylaxis against HIV infections.
BACKGROUND OF THE INVENTION
[0002] The Human Immunodeficiency virus (HIV) is the causative
agent of the Acquired Immunodeficiency Syndrome (AIDS). Like all
retroviruses the genome of the virus encodes the Gag, Pol and Env
proteins. In addition, the viral genome encodes further regulatory
proteins, i.e. Tat and Rev, as well as accessory proteins, i.e.
Vpr, Vpx, Vpu, Vif and Nef.
[0003] Despite public health efforts to control the spread of the
AIDS epidemic the number of new infections is still increasing. The
World Health Organization estimated the global epidemic at 36.1
million infected individuals at the end of the year 2000, 50%
higher than what was predicted on the basis of the data a decade
ago (WHO & UNAIDS. UNAIDS, 2000). Globally, the number of new
HIV-1 infections in 2000 is estimated at 5.3 million.
[0004] Given the steady spread of the epidemic, there is still a
need to bring an effective vaccine to the clinic. A number of
different HIV-1 vaccine delivery strategies such as novel vectors
or adjuvant systems have now been developed and evaluated in
different pre-clinical settings as well as in clinical trials. The
first vaccine candidate that entered a phase-III clinical trial is
based on envelope gp120 protein in alum (Francis et al., AIDS Res.
Hum. Retroviruses 1998; 14 (Suppl 3)(5): S325-31). The phase III
trials have been started although the vaccine did not prove to be
too successful in the earlier phase II trial.
[0005] Following many years of prophylactic vaccine efforts based
on envelope antigens, more recent efforts have focused on the use
of regulatory proteins such as Tat, Nef and Rev as candidate
vaccine antigens. The use of these regulatory antigens in
therapeutic settings has been ongoing for several years (Miller et
al., Nature Medicine 1997, 3, 389-94, Calarota et al., Lancet 1998,
351, 1320-5, Ayyavoo et al., AIDS, 2000, 14, 1-9). More recently
the use of these antigens in prophylactic vaccine studies in small
pre-clinical trials has revealed promise. The use of Tat and Rev,
or Tat alone as a prophylactic vaccine candidate, was demonstrated
to control SIVmac (Osterhaus et al., Vaccine 1999, 17, 2713-4).
Moreover, there are indications that CTL directed towards the virus
early regulatory proteins are important for eliminating infected
cells prior to their high level production of mature virions (van
Baalen et al., J. Gen. Virol 1997, 78, 1913-8; Addo et al., PNAS,
2001, 98, 1781-6).
[0006] Although the regulatory/accessory proteins of HIV induce an
effective immune response, most, if not all, of them have serious
side effects, which limit up to now their use as vaccine: Nef, Tat
and Vpu have been shown to play a role in the down regulation of
CD4+ and/or MHC class I expression (Howcroft et al., Science, 1993,
260, 1320-2; Schwartz et al., Nature Med. 1996, 2, 338-42; Swann et
al., Virology, 2001, 282, 267-77; Janvier et al., J. Virol., 2001,
78, 3971-6, Weissmann et al., PNAS 1998, 95, 11601-6). It is known
that Tat mediates acute immune suppression in vivo (Cohen et al.,
PNAS, 1999, 96, 10842-10847). Immunosuppressive effects have also
been described for Vpr (Ayyavoo et al., Nature Med., 1997, 3:
1117-1123). It has been described that Vpr and Vpx have
differential cytostatic and cytotoxic effects in yeast cells (Zhang
et al., Virology, 1997, 230, 103-12). Thus, most, if not all
accessory/regulatory proteins of HIV seem to have functional
properties that are not desired in a vaccine formulation.
[0007] Attempts to reduce the harmful effects of the HIV proteins
are disclosed in WO 02/06303. In particular, WO 02/06303 discloses
a fusion protein including amino acid sequences of HIV Vif, Vpu and
Nef, wherein the component proteins are contiguous with another
component protein or separated by non-component proteins such as
amino acid sequences, which make up proteolytic cleavage sites. It
is disclosed that it is preferred to use those fusion proteins that
comprise proteolytic cleavage sites between the component proteins.
Since the component proteins are separated by proteolytic cleavage
sites native HIV proteins are produced that are known to be
harmful. To reduce any harmful effects of the HIV proteins that
result from the cleavage of the fusion protein WO 02/06303 suggests
using attenuated proteins. Thus, WO 02/06303 teaches to use a
fusion protein comprising the HIV Vif, Vpr and Nef protein, wherein
cleavage sites are inserted between the HIV proteins and wherein
the HIV proteins are attenuated proteins. However, the disadvantage
of attenuated proteins is that the amino acid sequence of the
attenuated protein differs from the amino acid sequence of the
native protein so that an immunization with the attenuated protein
may lead to an immune response that only weakly recognizes the
native protein or that even does not recognize the native protein
at all.
OBJECT OF THE INVENTION
[0008] It was the object of the present invention to provide a
vaccine allowing the generation of an effective immune response, in
particular an effective cytotoxic T cell response, against several
or all regulatory/accessory proteins of HIV, wherein the
regulatory/accessory HIV proteins in the vaccine or produced by the
vaccine are less functional than the native, individual
regulatory/accessory proteins so that the risk is reduced that the
accessory/regulatory proteins in the vaccine exert undesired side
effects and wherein the less active HIV proteins induce a similar
immune response than the native HIV proteins.
DETAILED DESCRIPTION OF THE INVENTION
[0009] This object has been achieved by the provision of a fusion
protein comprising the amino acid sequence of at least four
different HIV proteins selected from Vif, Vpr, Vpu, Vpx, Rev, Tat
and Nef or derivatives of the amino acid sequence of one or more of
said proteins, wherein the fusion protein is not processed to
individual HIV proteins having the natural N and C termini. In
particular the object of the present invention has been achieved by
nucleic acids and vectors encoding said fusion proteins.
[0010] If the fusion protein is produced in animal cells, including
human cells, the fusion protein is not cleaved by cellular
proteases in such a way that accessory/regulatory proteins with
native N- and C-termini are obtained. Due to the fact that an HIV
protein that is part of a fusion protein has an altered
secondary/tertiary structure compared to the individual HIV
protein, the HIV protein in the fusion protein is less functional
than the individual protein, if not fully dysfunctional. A
regulatory/accessory protein that is less functional or even not
functional at all does not have the undesired side effects of the
HIV protein in its native conformation. As far as the
immunogenicity is concerned there is no substantial difference when
the immunogenicity of the fusion protein is compared with the
immunogenicity of the individual HIV regulatory/accessory proteins
that form the fusion protein. In particular there is no substantial
difference with respect to the cytotoxic T cell (CTL) response
since the epitopes that are presented to the immune system are
identical. The same considerations also apply if the fusion protein
is administered to the patient.
[0011] In the context of the present invention the term "HIV"
refers to any HIV group, subtype (clade), strain or isolate known
to the person skilled in the art. In particular, HIV may be HIV-1
or HIV-2. HIV-1 has been classified in nine subtypes (clades A
through 1), whereas HIV-2 has been classified in five subtypes (A
through E), which are all covered by the scope of the present
invention. The most preferred HIV clades according to the present
invention are HIV-1 clades A, B and C. However, the invention is
not restricted to these most preferred clades.
[0012] The protein sequences of the HIV regulatory proteins Vif,
Vpr, Vpu, Rev, Tat, Vpx and Nef are known to the person skilled in
the art. By way of example and without being restricted to said
embodiments reference is made to the various sequences as disclosed
in the genebank database, in particular to the sequence of the
HIV-1 isolate HXB2R having the genebank accession number K03455. In
this genebank entry the sequences of the various HIV1 genes and of
the proteins encoded by said genes is specified.
[0013] Preferably the HIV proteins that form the fusion protein are
derived from the same lade. According to an alternative embodiment
the HIV proteins that form the fusion protein are derived from two
or more clades. It is also possible that one or more of the HIV
proteins that form the fusion protein are HIV-1 proteins and that
one or more of the HIV proteins that form the fusion protein are
HIV-2 proteins.
[0014] The amino acid sequences of the HIV proteins that form the
fusion protein are preferably sequences that are encoded by known
HIV isolates, i.e. the amino acid sequence of the HIV proteins in
the fusion protein is identical to the amino acid sequences of the
corresponding proteins as encoded by naturally occurring HIV
isolates. Alternatively the amino acid sequence of one or more HIV
proteins in the fusion protein may be a consensus sequence, i.e. a
sequence that as such may not be found in a known HIV isolate but
that shows an optimal homology--in particular with respect to
CTL-epitopes--to several or all known HIV isolates. Computer
algorithms to calculate a consensus sequence are known to the
person skilled in the art.
[0015] In an alternative embodiment the fusion protein may comprise
derivatives of the amino acid sequence of one or more HIV proteins
that are part of the fusion protein. The term "derivative of the
amino acid sequence of an HIV protein" as used in the present
specification refers to HIV proteins that have an altered amino
acid sequence compared to the corresponding naturally occurring HIV
protein. An altered amino acid sequence may be a sequence in which
one or more amino acids of the sequence of the HIV protein are
substituted, inserted or deleted. More particularly a "derivative
of the amino acid sequence of an HIV protein" is an amino acid
sequence showing a homology of at least 50%, more preferably of at
least 70%, even more preferably of at least 80%, most preferably of
at least 90% when the corresponding part of the amino acid sequence
in the fusion protein is compared to the amino acid sequence of the
respective HIV protein of known HIV isolates. An amino acid
sequence is regarded as having the above indicated sequence
homology even if the homology is found for the corresponding
protein of only one HIV isolate, irrespective of the fact that
there might be corresponding proteins in other isolates showing a
lower homology. By way of example, if a Vpr derivative in the
fusion protein shows a homology of 95% to the Vpr sequence of one
HIV isolate, but only a homology of 50-70% to (all) other HIV
isolates, the homology of said Vpr derivative is regarded as being
of at least 90%.
[0016] It has been pointed out above that the HIV proteins in the
fusion protein have a reduced activity, or even no activity at all,
compared to the individual proteins, since the conformation of the
proteins in the fusion protein is different to the natural
conformation of the biologically active proteins. However, it might
be desirable to further reduce the risk that the HIV proteins in
the fusion protein are biologically active. To this end
particularly preferred "derivatives" of an individual HIV protein
that is part of a fusion protein are amino acid sequence
derivatives in which several amino acids are deleted, inserted or
substituted, more preferably not more than 10 amino acids, most
preferably not more than 5 amino acids to obtain an HIV protein
with reduced activity or no activity at all. Tests are known to the
person skilled in the art how to determine whether an HIV protein
has reduced biological activity:
[0017] The molecular mechanism of the Vif protein, which is
essential for viral replication in vivo, remains unknown, but Vif
possesses a strong tendency toward selfassociation. This
multimerization was shown to be important for Vif function in viral
life cycle (Yang S. et al., J Biol Chem 2001; 276: 4889-4893).
Additionally vif was shown to be specifically associated with the
viral nucleoprotein complex and this might be functionally
significant (Khan M. A. et al., J. Virol. 2001; 75 (16): 7252-65).
Thus, a vif protein with reduced activity shows a reduced
multimerization and/or association to the nucleoprotein
complex.
[0018] The Vpr protein plays an important role in the viral life
cycle. Vpr regulates the nuclear import of the viral preintegration
complex and facilitates infection of non dividing cells such as
macrophages (Agostini et al., AIDS Res Hum Retroviruses 2002;
18(4):283-8). Additionally, it has transactivating activity
mediated by interaction with the LTR (Vanitharani R. et al.,
Virology 2001; 289 (2):334-42). Thus, a vpr with reduced activity
shows decreased or even no transactivation and/or interaction with
the viral preintegration complex.
[0019] Vpx, which is highly homologous to Vpr, is also critical for
efficient viral replication in non-dividing cells. Vpx is packaged
in virus particles via an interaction with the p6 domain of the gag
precursor polyprotein. Like Vpr Vpx is involved in the
transportation of the preintegration complex into the nucleus
(Mahalingam et al., J. Virol 2001; 75 (1):362-74). Thus, a Vpx with
reduced activity has a decreased ability to associate to the
preintegration complex via gag precurser.
[0020] The Vpu protein is known to interact with the cytoplasmic
tail of the CD4 and causes CD4 degradation (Bour et al., Virology
1995; 69 (3):1510-20). Therefore, Vpu with reduced activity has a
reduced ability to trigger CD4 degradation.
[0021] The relevant biological activity of the well-characterized
Tat protein is the transactivation of transcription via interaction
with the transactivation response element (TAR). It was
demonstrated that Tat is able to transactivate heterologous
promoters lacking HIV sequences other than TAR (Han P. et al.,
Nucleic Acid Res 1991; 19 (25):7225-9). Thus, a tat protein with
reduced activity shows reduced transactivation of promoters via the
TAR element.
[0022] Nef protein is essential for viral replication responsible
for disease progression by inducing the cell surface downregulation
of CD4 (Lou T et al., J Biomed Sci 1997;4(4):132). This
downregulation is initiated by direct interaction between CD4 and
Nef (Preusser A. et al., Biochem Biophys Res Commun 2002;292
(3):734-40). Thus, Nef protein with reduced function shows reduced
interaction with CD4.
[0023] The relevant function of Rev is the posttranscriptional
transactivation initiated by interaction with the Rev-response
element (RRE) of viral RNA (Iwai et al., 1992; Nuceic Acids Res
1992; 20 (24):6465-72). Thus, a Rev with reduced activity shows a
reduced interaction with the RRE.
[0024] The fusion proteins according to the present invention
comprise the amino acid sequence of at least four different HIV
proteins selected from Vif, Vpr, Vpu, Rev, Vpx, Tat and Nef. The
fusion protein may preferably comprise 5, 6 or all of said HIV
proteins. The order of the HIV proteins in the fusion protein is
not critical.
[0025] One or more of the at least four different HIV proteins may
be comprised in the fusion protein in two or more copies. Thus, by
way of example a fusion protein according to the present invention
may comprise Vif, Vpr, Vpu and two copies of Rev. The amino acid
sequence of the two or more copies of a HIV protein may be
identical. Alternatively, the amino acid sequence of the copies may
be different, in particular if protein sequences are used that are
derived from different HIV strains or clades (e.g. one copy of an
HIV-1 Rev and one copy of an HIV-2 Rev).
[0026] Adjacent HIV proteins in the fusion protein may be fused
without additional amino acids or fused in such a way that two
adjacent HIV proteins in the fusion protein are separated by at
least one additional amino acid. Also combinations of both are
within the scope of the present invention. By way of example, in a
fusion protein according to the present invention comprising the
amino acid sequence of four HIV proteins two adjacent HIV proteins
may be directly linked to each other, whereas the third and fourth
HIV proteins are linked via additional amino acids. The term
"additional amino acid" in the context of this embodiment refers to
amino acids that are not found in this position in the naturally
occurring HIV proteins.
[0027] Thus, the fusion protein according to the present invention
preferably has the following general formula:
+P1---P2---P3---P4---P5*---P6*---P7*+
[0028] wherein P1 to P7 are different HIV proteins selected from
Vif, Vpr, Vpx, Vpu, Tat, Rev and Nef, wherein the fusion protein
comprises at least four different of said HIV proteins, i.e. P1 to
P4 and optionally one (P5*), two (P5*---P6*) or three
(P5*---P6*---P7*) additional of said HIV proteins. The abbreviation
"---" independently stands for 0 to n additional amino acids. When
"---" stand for 0 amino acids, the adjacent HIV proteins are
directly fused to each other without additional amino acids. When
"---" stands for 1 to n amino acids the adjacent HIV proteins are
separated by one to n amino acids. The upper limit of the
additional amino acids, i.e. the integer n, depends on the maximal
size of the fusion protein that can be produced or expressed in
cells.
[0029] According to one embodiment all "---" stand independently
for 0 to 20, more preferably 0 to 10, even more preferably 0 to 5
additional amino acids.
[0030] According to an alternative embodiment at least one of "---"
stands for the amino acid sequence of an additional protein or a
part thereof, which is not an HIV protein selected from Vif, Vpr,
Vpx, Vpu, Rev, Tat and Nef. Thus, according to this alternative
embodiment the additional protein is flanked by
regulatory/accessory HIV proteins. The additional protein may be
any protein. More preferably the additional protein comprises
additional epitopes that may help to induce a better immune
response against HIV. Thus, the additional protein may be the HIV
Env, Gag and/or Pol protein or parts thereof. In this context the
term "part" of Env, Gag and Pol refers to an amino acid stretch
derived from one of said protein, which comprises at least one
epitope. More preferably the term part refers to at least 10, even
more preferably to at least 20, most preferably to at least 50
amino acids from one of said proteins. According to an related
embodiment at least one of "---" stands for the amino acid sequence
of one or more of the proteins P1 to P7 that are part of the fusion
protein. Thus, in this case the fusion protein may comprise one or
more copies of one or more of the proteins that are part of the
fusion protein. As pointed out the copies of the proteins may or
may not have an identical amino acid sequence.
[0031] In the above formula the abbreviation "+" independently
stands for 0 to n additional terminal amino acid. Thus, the fusion
protein according to the present invention may or may not comprise
additional amino acids at the C and/or N-terminus of the protein.
According to one embodiment at least one of "+" stands for the
amino acid sequence of an additional protein or part thereof, which
is not an HIV protein selected from Vif, Vpr, Vpx, Vpu, Rev, Tat
and Nef. Thus, according to this embodiment the fusion protein
comprises at its C and/or N terminus an additional protein, which
is not Vif, Vpr, Vpx, Vpu, Rev, Tat or Nef. The additional protein
may be any protein. More preferably the additional protein
comprises additional epitopes that may help to induce a better
immune response against HIV. E.g., the additional protein may be
the HIV Env, Gag and/or Pol protein or parts thereof. In this
context the term "part" of Env, Gag and Pol refers to an amino acid
stretch derived from one of said protein, which comprises at least
one epitope. More preferably the term part refers to at least 10,
even more preferably to at least 20, most preferably to at least 50
amino acids from one of said proteins.
[0032] According to an alternative embodiment at least one of "+"
stands for an amino acid sequence that allows the easy detection or
purification of the fusion protein. Thus, at least one of "+" might
for example be a tag such as a His tag.
[0033] According to the present invention the fusion protein is not
processed to individual HIV proteins having the natural N- and
C-termini. More particularly, the fusion protein according to the
present invention is not processed to individual HIV proteins
having the natural N- and C-termini, when expressed in human cells.
Methods are known to the person skilled in the art how to check
whether a fusion protein when expressed in human cells is processed
to individual HIV proteins having the natural N- and C-termini. In
this context reference is made to Ayyavoo et al., AIDS 2000, 14,
1-9, in particular to the experiment disclosed in FIG. 2 of said
publication. Briefly, the person skilled in the art might easily
express the respective fusion protein in human cells such as HeLa
cells; the cells are then lysed and the cell lysates are subjected
to Western blotting experiments or immunoprecipitation assays with
antibodies specific for the individual HIV proteins that together
form the respective HIV fusion protein. For a fusion protein
according to the present invention no significant amount of HIV
proteins is detected the size of which corresponds to the size of
an individual HIV regulatory/accessory protein.
[0034] In order to ensure that the fusion protein according to the
present invention is not processed to individual HIV proteins
having the natural N- and C-termini, the fusion protein should not
contain specific cleavage sequences for cellular proteases, which
might trigger the generation of HIV proteins having the natural N-
and C-termini, between the amino acid sequences of the HIV proteins
that form the fusion protein. Thus, the amino acid sequence "---"
as abbreviated in the above general formula does not contain
specific cleavage sequences for cellular proteases, which might
trigger the generation of HIV proteins having the natural N- and
C-termini. In particular the fusion protein does not contain the
cleavage sequence REKRAWG (one letter amino acid code) between the
amino acid sequences of the different HIV proteins that form the
fusion protein. Further cleavage sequences for cellular proteases
are known to the person skilled in the art. Thus, the person
skilled in the art can easily avoid to include cleavage sequences
for (cellular) proteases that might lead to individual HIV proteins
having natural N- and C-termini. An example for the cleavage
sequence of a cysteinprotease is Ile/leu-X-Thr-X-Gly.
[0035] The proteins according to the present invention do not
comprise specific cleavage sequences leading to HIV proteins having
both, the native N- and C-termini. However, this does not generally
exclude the presence of cleavage sites for cellular proteases
between the proteins in the fusion protein as long as these
cleavage sites do not mediate the generation of HIV proteins having
both, a natural N-terminus and a natural C-terminus. In particular,
the amino acid sequence "---" as abbreviated in the above general
formula may comprise cleavage sites for the proteases that are
involved in the generation of short peptides presented on MHCl or
MHClI. According to this embodiment the result of the cleavage
reaction is a short peptide stretch of preferably less than 20
amino acids, the N- or C-terminus of which may correspond to the N-
or C-terminus of one of the HIV accessory/regulatory proteins.
However, these short peptides, when produced during the process of
presentation of antigens, do not have anymore the activity of the
HIV protein from which they are derived.
[0036] The invention further relates to nucleic acids encoding the
above defined fusion proteins according to the present invention.
The nucleic acid may be DNA or RNA. Preferably the nucleic acid is
DNA if it is intended to insert the nucleic acid into human cells
by using a DNA vector such as a plasmid or a vector based on a DNA
virus.
[0037] Methods are known to the person skilled in the art how to
construct a nucleic acid encoding the fusion protein according to
the present invention. Without being bound to the following
methods, the person skilled in the art may start from a genomic HIV
clone, from a subgenomic HIV clone or from any starting material,
such as plasmids, comprising the coding sequence of one or more of
the regulatory/accessory HIV proteins. If the coding sequence of a
regulatory/accessory protein is in the form of a continuous reading
frame, said coding sequence may be isolated by cleaving the nucleic
acid comprising said coding sequence with appropriate restriction
enzymes. The thus obtained DNA fragments may be used for further
cloning. Alternatively the coding sequences of an
accessory/regulatory protein may be obtained by using Polymerase
Chain Reaction (PCR) methods with appropriate primers. If the
regulatory/accessory proteins are encoded by more than one exon, as
it is the case e.g. for Tat and Rev, it may be necessary to
independently clone the different exons and to fuse them to
generate a continuous reading frame for the regulatory/accessory
protein or to use reverse transcription technology such as
RT-PCR.
[0038] A coding sequence can also be provided by gene synthesis,
i.e. by generating a gene using a set of complementary and/or
overlapping oligonucleotides.
[0039] In order to obtain a fusion protein the nucleic acid
encoding said fusion protein preferably contains a continuous
reading frame. Consequently, the stop codons of all but the last
sequence encoding HIV proteins or additional proteins are
preferably mutated into a codon coding for an amino acid or deleted
completely. Preferably, this can be easily achieved if for PCR
specific primers are used that amplify the coding sequence without
the stop codon. In other words, according to this alternative the
downstream primer should not be complementary to the stop codon.
The amplified DNA fragment therefore will not contain a stop codon
and can be cloned into the cloning vector. Alternatively, it is
also possible to clone a coding sequence with its stop codon into
the cloning vector. The stop codon can be deleted later, e.g. by
using specific endonucleases or by mutagenization.
[0040] The result of the cloning steps should be a continuous
reading frame encoding the fusion protein according to the present
invention.
[0041] The regulatory elements that are necessary to obtain the
expression of the fusion protein may be any regulatory elements
that drive the expression in the desired expression system. If it
is intended to produce the fusion protein in prokaryotic cells such
as Escherichia coli it is preferable to use a bacterial or phage
promoter. If it is intended to express the fusion protein in
eukaryotic cells it is preferable to use an eukaryotic or viral
promoter/enhancer. If it is intended to express the fusion protein
by using a poxyiral promoter (see below) it is preferable to use a
poxyiral promoter such as the 7.5 promoter or the ATI promoter.
[0042] As pointed out above the fusion protein may comprise fusion
partners which are not HIV proteins selected from Vif, Vpr, Vpx,
Vpu, Tat, Rev and Nef. Thus, the fusion protein may comprise the
amino acid sequence of other proteins or parts thereof. Examples of
other proteins are the HIV Gag, Pol and Env proteins. Consequently,
the nucleic acid according to the present invention may comprise
also the coding sequences for one or more additional proteins or
part thereof in the open reading frame encoding at least four
regulatory/accessory HIV proteins or derivatives thereof.
[0043] In a further embodiment of the present invention the nucleic
acid may further comprise independent expression cassettes encoding
additional proteins that may help to further improve the immune
response against HIV. In a preferred embodiment the nucleic acid
may further comprise expression cassettes comprising the coding
sequence of at least one additional HIV protein selected from Gag,
Pol and Env or parts thereof. Even more preferably the nucleic acid
may comprise in addition to the coding sequence of the fusion
protein the coding sequences of all HIV proteins Gag, Pol and Env.
The nucleic acid is preferably part of a vector. The nucleic acid
may also be the viral genome or part thereof of a viral vector,
preferably a poxvirus vector such as MVA. Thus, it is possible to
express from the poxyiral vector the fusion protein as well as the
additional HIV proteins, e.g. at least one additional HIV protein
selected from Gag, Pol and Env.
[0044] The invention further relates to vectors comprising a
nucleic acid according to the present invention. The term "vector"
refers to any vectors known to the person skilled in the art. A
vector can be a plasmid vector such as pBR322 or a vector of the
pUC series. More preferably the vector is a virus vector. In the
context of the present invention the term "viral vector" or "virus
vector" refers to an infectious and/or attenuated virus comprising
a viral genome. In this case the nucleic acid of the present
invention is part of the viral genome of the respective viral
vector and/or constitutes the viral genome. The recombinant vectors
can be used for the infection of cells and cell lines, in
particular for the infection of living animals including humans.
Typical virus vectors according to the present invention are
adenoviral vectors, retroviral vectors or vectors on the basis of
the adeno associated virus 2 (AAV2). Most preferred are poxyiral
vectors. The poxvirus may be preferably a canarypox virus, a
fowlpoxvirus or a vaccinia virus. More preferred is modified
vaccinia virus Ankara (MVA) (Sutter, G. et al. [1994], Vaccine 12:
1032-40). A typical MVA strain is MVA 575 that has been deposited
at the European Collection of Animal Cell Cultures under the
deposition number ECACC V00120707. Most preferred is MVA-BN or a
derivative thereof, which has been described in the PCT application
PCT/EP01/13628 filed at the European Patent Office on Nov. 22,
2001, entitled "Modified Vaccinia Ankara Virus Variant". MVA-BN has
been deposited at the European Collection of Animal Cell Cultures
with the deposition number ECACC V00083008. By using MVA-BN or a
derivative thereof the additional technical problem has been solved
to provide a particular safe virus vaccine against HIV since the
MVA-BN virus vector is an extremely attenuated virus, which is
derived from Modified Vaccinia Ankara virus and which is
characterized by the loss of its capability to reproductively
replicate in human cells. MVA-BN is safer than any other known
vaccinia virus strains due to a lack of replication in humans. In a
preferred embodiment the invention concerns as a viral vector
containing the DNA according to the present invention MVA-BN and
derivatives of MVA-BN. The features of MVA-BN, the description of
biological assays allowing to evaluate whether a MVA is MVA-BN or a
derivative thereof and methods allowing to obtain MVA-BN or a
derivative thereof are disclosed in the above referenced PCT
application PCT/EP01/13628, which is herewith incorporated by
reference.
[0045] Thus, according to these embodiments the invention concerns
preferably a recombinant MVA, such as MVA-BN, comprising in the
viral genome an expression cassette encoding a fusion protein
according to the present invention.
[0046] Methods to insert the nucleic acid according to the present
invention into the viral genome and methods to obtain recombinant
viruses are known to the person skilled in the art.
[0047] In a recombinant vaccinia virus the expression of the DNA
according to the present invention is preferably, but not
exclusively, under the transcriptional control of a poxvirus
promoter, more preferably of a vaccinia virus promoter. The
insertion of the DNA according to the present invention is
preferably into a non-essential region of the virus genome. In
another preferred embodiment of the invention, the heterologous
nucleic acid sequence is inserted at a naturally occurring deletion
site of the poxyiral genome (disclosed in PCT/EP96/02926). However,
the nature of the insertion site is not critical for the present
invention as long as a recombinant Vaccinia virus is obtained.
Thus, the person skilled in the art may easily envisage further
suitable insertion sites.
[0048] Preferably the viral vector, in particular the poxyiral
vector may comprise additional retroviral genes selected from HIV
Gag, Pol and Env genes in the viral genome, in addition to the
coding sequence for the fusion protein according to the present
invention. More preferably the viral vector, in particular the
poxyiral vector, may comprise all HIV genes encoding Gag, Pol and
Env in addition to the coding sequence for the fusion protein
according to the present invention. These additional genes might
have been inserted with the same nucleic acid according to the
present invention. According to this embodiment all HIV genes would
be located in the same insertion site in the viral genome. In an
alternative embodiment the additional genes are inserted in
different locations of the viral genome.
[0049] In a preferred embodiment the present invention concerns the
nucleic acid, the vector or the fusion protein according to the
present invention as a vaccine for the at least partial prophylaxis
against HIV infections and AIDS. A "vaccine" is a compound, i.e. a
nucleic acid, a fusion protein, a vector or a virus that induces a
specific immune response.
[0050] According to one alternative of this embodiment the
"vaccine" according to the present invention is based on the fusion
protein according to the present invention.
[0051] In a preferred embodiment the nucleic acid according to the
present invention, in particular DNA, is used as a vaccine. It is
known by the person skilled in the art that the administration of
naked DNA harboring a eukaryotic expression cassette as in the
present invention, in particular the intramuscular injection of DNA
leads to the expression of the protein encoded by the expression
cassette. The protein is exposed to the immune system and a
specific immune response is raised.
[0052] In an alternative embodiment the vaccination is made by
administering a vector according to the present invention, in
particular a viral vector, more preferably a poxvirus vector, most
preferably a vaccinia virus vector, e.g. a MVA vector.
[0053] For the preparation of a vaccinia virus based vaccine, the
virus according to the invention is converted into a
physiologically acceptable form. This can be done based on the
experience in the preparation of poxvirus vaccines used for
vaccination against smallpox (as described by Stickl, H. et al.
[1974] Dtsch. med. Wschr. 99, 2386-2392). For example, the purified
virus is stored at -80.degree. C. with a titer of 5.times.10.sup.8
TCID.sub.50/ml formulated in about 10 mM Tris, 140 mM NaCl pH 7.4.
For the preparation of vaccine shots, e.g., 10.sup.2-10.sup.8
particles of the virus are lyophilized in 100 ml of
phosphate-buffered saline (PBS) in the presence of 2% peptone and
1% human albumin in an ampoule, preferably a glass ampoule.
Alternatively, the vaccine shots can be produced by stepwise
freeze-drying of the virus in a formulation. This formulation can
contain additional additives such as mannitol, dextran, sugar,
glycine, lactose or polyvinylpyrrolidone or other additives such as
antioxidants or inert gas, stabilizers or recombinant proteins
(e.g. human serum albumin) suitable for in vivo administration. The
glass ampoule is then sealed and can be stored between 4.degree. C.
and room temperature for several months. However, as long as no
need exists the ampoule is stored preferably at temperatures below
-20.degree. C. For vaccination the lyophilisate can be dissolved in
0.1 to 0.5 ml of an aqueous solution, preferably physiological
saline or Tris buffer, and administered either systemically or
locally, i.e. by parenterally, intramuscularly or any other path of
administration know to the skilled practitioner. The mode of
administration, the dose and the number of administrations can be
optimized by those skilled in the art in a known manner. Most
preferred for poxvirus vectors is subcutaneous or intramuscular
administration.
[0054] If the vaccine is a MVA-BN vector or derivative thereof
comprising a DNA according to the present invention, a particular
embodiment of the present invention concerns the administration of
the vaccine in therapeutically effective amounts in a first
inoculation ("priming inoculation") and in a second inoculation
("boosting inoculation").
[0055] If the vaccine is a MVA-BN vector or derivative thereof
comprising a DNA according to the present invention a particular
embodiment of the present invention concerns a kit for vaccination
comprising a MVA-BN virus vector according to the present invention
for the first vaccination ("priming") in a first vial/container and
for a second vaccination ("boosting") in a second
vial/container.
[0056] Thus the invention concerns in the vaccine embodiments a
vaccine comprising a nucleic acid, a vector or a fusion protein
according to the present invention and the use of said nucleic
acid, vector or protein for the preparation of a vaccine.
[0057] According to a further embodiment the invention concerns a
method for protecting an animal, including a human, against an HIV
infection by administering to an animal, including a human, in need
thereof a fusion protein according to the present invention, a
nucleic acid according to the present invention or a vector
according to the present invention.
[0058] Moreover, the invention concerns a method of producing a
protein according to the present invention, comprising the steps of
(i) transfecting a host cell with a nucleic acid or a vector
according to the present invention or (ii) infecting a host cell
with a viral vector according to the present invention, (iii)
expressing the fusion protein in the transfected host cell of step
(i) or the infected host cell of step (ii), and (iv) recovering the
fusion protein.
[0059] The invention further relates to host cells transfected with
a nucleic acid or a vector according to the present invention or
infected with a viral vector according to the present
invention.
[0060] According to an alternative embodiment the fusion protein
may comprise at least three different HIV proteins selected from
Vif, Vpr, Vpu, Rev, Vpx and Tat. The fusion protein may preferably
comprise 4, 5 or all of said HIV proteins. A typical fusion protein
according to this embodiment comprises the amino acid sequence of
the HIV proteins Vpr, Vif, Vpu, Rev and Tat or derivatives of the
amino acid sequence of one or more of said proteins. As pointed out
above, the order of the HIV proteins in the fusion protein is not
critical. All preferred embodiments as specified above also apply
for this alternative embodiment.
SHORT DESCRIPTION OF THE FIGURES
[0061] FIG. 1: Schematic presentation of Annealing of
Oligonucleotides
[0062] The picture shows the annealing of four Oligonucleotides.
They are single stranded and can be annealed by complementary ends.
The gaps are filled in with a polymerase, which exhibits a
proofreading activity (eg Pfx polymerase).
[0063] FIG. 2: Schematic presentation of annealing of four genes of
the blob
[0064] The vif gene shows a overlapping sequence with the vpr
fragment, the vpu coding fragment shows an overlapping sequence
with the rev gene (grey). The PCR fragments are denatured and the
overlapping complementary ends are hybridized. The resulting gaps
are filled using Pfx polymerase. The vif-vpr fragment is fused to a
overlapping sequence of the vpu-rev fragment, which again is used
for fusion.
[0065] FIG. 3: Cloning strategy of the sequence encoding a fusion
protein according to the present invention in a recombination
vector for insertion of foreign genes into the MVA genome
[0066] The fused vif, vpr, vpu and rev polyprotein coding region
was amplified with primers comprising a ClaI and ApaI restriction
site. This pCR product was cloned into the ClaI/ApaI cutted vector
pBNX65, which contains the Poxvirus ATI promoter. The tat coding
region was amplified by PCR with primers containing an Acc651
restriction site and ligated to the Acc651 linearized
pBNX65+vif-rev. The resulting expression cassette (ATI
promoter+sequence encoding a fusion protein according to the
present invention) was isolated by PacI restriction and inserted in
the recombination vector for insertion of foreign genes in the MVA
genome I4L intergenic region (pBNX39). PBNX39 contains sequences
homologous to the flanking sequences of the insertion site of the
MVA genome (F1 I4L and F2 I4L). For selection of recombinant
viruses after homologous recombination of the MVA genome and pBNX39
the vector additionally contains the E. coli gpt gene
(phosphoribosyltransferase gene). After purification of recombinant
viruses, the selection cassette is deleted by homologous
recombination between Flank 1 and a repeat sequence of flank 1
(F1rpt).
[0067] FIG. 4: Schematic presentation of the MVA genome
[0068] MVA contains a linear genome, which shows characteristic
fragments after restriction with Hind III (A-O). The non functional
region between the I4L and the I5L genes is located in the I
fragment. Insertion of foreign genes using pBNX39 occurs at
position 56767-56768.
EXAMPLES
Generation of a DNA Encoding a HIV Vif-Vpr-Vpu-Rev-Tat Fusion
Protein
[0069] The single genes of the HIV genome were either prepared by
PCR out of genomic DNA by using standard PCR protocols or
synthetically by a technique, which is based on the annealing of
oligonucleotides via overlapping sequences and fill in of the
resulting single stranded gaps.
[0070] For the oligonucleotide based generation of coding regions
of genes, which are to be inserted into the nucleic acid encoding
the fusion protein according to the present invention, 40mer
oligonucleotides with 15 bp overlaps were designed. The sequence of
the oligonucleotides is based on the genomic map of the HIV1
isolate HXB2R that is derived from strain IIIB. The
oligonucleotides for the annealing reaction or the PCR for
isolation of the required sequence were designed in that way, that
in the resulting coding region the stop codons for translation
termination were deleted. The tat gene was synthesized using oligos
containing a Stop codon as this gene was to be inserted at the last
postion of the nucleic acid encoding the fusion protein according
to the present invention and therefore should contain a stop
triplet for a correct termination of translation of the
polyprotein.
[0071] For the oligoannealing rection 10 cycles of a two step Pfx
polymerase (Gibco-BRL) reaction (denaturation at 95.degree. C. and
annealing/extension at 68.degree. C.) were performed. During that
reaction the overlapping sequences of the oligos become annealed
and the gaps are filled in by Pfx proofreading polymerase (FIG.
1).
[0072] For synthesis of the vif coding region, the first encoded
gene in the nucleotide sequence encoding the fusion protein, a PCR
using genomic HIV cDNA was performed. The PCR was performed in that
way, that the vif coding region was fused to the first 15 bp of the
following vpr gene for the subsequent annealing of vif and vpr. The
Vpr coding region, which covers bp 5559-5847 of the HIV HXB2R
genome, was prepared by annealing of 10 oligonucleotides. The
resulting gaps were filled and after subsequent PCR for
amplification the product contained the vpr coding region fused to
flanking regions for vif and vpu, which was to be inserted after
vpr coding region.
[0073] The Vpu coding region was amplified by PCR out of the same
cDNA used for synthesis of vif and the resulting product contained
the flanking regions for fusion with vpr and rev.
[0074] The rev coding region was synthesized by annealing of 14
oligonucleotides, which cover the region bp 5970-6045 and 8379-8650
of the HIV HXB2R genome and 15 bp overlaps for annealing with vpu
and tat.
[0075] The tat coding region was created by using 10
oligonucleotides, which cover bp 5831-6045 and 8379-8466 of of the
HIV HXB2R genome.
[0076] The vif and the vpr coding region as well as the vpu and the
rev coding region were fused by annealing of the two fragments via
their overlaps with a two step Pfx polymerase reaction (FIG. 2).
After additional PCR amplification of the fusion products, the
fragments were purified and ligated to each other via the overlap
of vpr and vpu (FIG. 2). After PCR amplification of the resulting
product (coding sequences for vif-vpr-vpu-rev) the tat coding
region was fused by cloning of the vif-vpr-vpu-rev fragment and tat
in adjacent cloning sites in a pBluescriptKS+ vector containing the
poxvirus ATI promoter (FIG. 3, pBNX65). The complete expression
cassette was then isolated by PacI restriction and inserted in
pBNX39 (FIG. 3). PBNX39 contains sequences homologous to the MVA
genome, which allows insertion in a non coding region (I4L) of the
genome (FIG. 4) by homologous recombination.
* * * * *